/
Immunology
Myasthenia Gravis
39
Pipeline Programs↗
91
Active Trials↗
37
Companies Involved↗
Myasthenia Gravis is a moderately active landscape with 39 programs across 37 companies. The most active players are Argenx, UCB, AstraZeneca. 15 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical12
Phase 16
Phase 26
Phase 315
Approved
No programs
Analysis
Modality Breakdown
33programs
Small molecule1855%
Monoclonal antibody824%
Cell therapy515%
Protein / enzyme13%
RNA therapy13%
Modality classified for 90% of 39 pipeline programs.
Analysis
Trial Status
173
clinical trials
Recruiting56 · 32%
Completed55 · 32%
Not yet recruiting17 · 10%
Active, not recruiting14 · 8%
Terminated14 · 8%
Unknown status10 · 6%
Other7 · 4%
Clinical Trials
Trial Activity
173 trials
Page 1 of 12
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)